You are 3 steps away
from making better decisions

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
McKesson
Boehringer Ingelheim
Dow

Last Updated: August 7, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR BGB-A317

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Clinical Trials for BGB-A317

Trial ID Title Status Sponsor Phase Summary
NCT02343120 Study of the Safety and Pharmacokinetics of BGB-3111 in Subjects With B-Cell Lymphoid Malignancies Recruiting BeiGene Phase 1 This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-3111 in patients with B-Cell Lymphoid Malignancies.
NCT02361723 Study of the Safety and Pharmacokinetics of BGB-290 in Subjects With Solid Tumors Recruiting BeiGene Phase 1 This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-290 in patients with solid tumors.
NCT02569476 BGB 3111 in Combination With Obinutuzumab in Subjects With B-Cell Lymphoid Malignancies Recruiting BeiGene Phase 1 This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with obinutuzumab in subjects with B-cell lymphoid malignancies.
NCT02610361 Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors Active, not recruiting BeiGene Phase 1 This study will evaluate the safety, tolerability, pharmacokinetic profile and treatment effect of a new drug known as BGB-283 in patients with solid tumours.
NCT02660034 The Safety, Pharmacokinetics and Antitumor Activity of the BGB-A317 in Combination With the BGB-290 in Subjects With Advanced Solid Tumors Recruiting Myriad Genetic Laboratories, Inc. Phase 1 The Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Subjects With Advanced Solid Tumors
>Trial ID >Title >Status >Phase >Summary

Clinical Trial Conditions for BGB-A317

Condition Name

Condition Name for
Intervention Trials
Solid Tumors 4
Classical Hodgkin Lymphoma 3
Marginal Zone Lymphoma 3
Healthy Volunteers 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for
Intervention Trials
Lymphoma 16
Carcinoma 8
Neoplasms 7
Leukemia, Lymphocytic, Chronic, B-Cell 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for BGB-A317

Trials by Country

Trials by Country for
Location Trials
China 193
United States 87
Australia 44
Japan 19
France 13
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for
Location Trials
California 8
Texas 7
Ohio 6
Tennessee 6
Florida 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for BGB-A317

Clinical Trial Phase

Clinical Trial Phase for
Clinical Trial Phase Trials
Phase 3 15
Phase 2 21
Phase 1/Phase 2 8
[disabled in preview] 23
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for
Clinical Trial Phase Trials
Recruiting 33
Not yet recruiting 25
Active, not recruiting 5
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for BGB-A317

Sponsor Name

Sponsor Name for
Sponsor Trials
BeiGene 56
BeiGene USA, Inc. 3
M.D. Anderson Cancer Center 2
[disabled in preview] 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for
Sponsor Trials
Industry 65
Other 12
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Boehringer Ingelheim
Johnson and Johnson
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.